国药控股维持跑赢行业评级,目标价24.7港元

中金公司
Oct 30, 2025

一、核心观点与评级维持中金公司 在研报中维持对国药控股(01099)的“跑赢行业”评级,并给出目标价24.7港元。基于对公司2025年和2026年的盈利预测,中金预计其净利润将分别达到74.75亿元人民币和79.26亿元人民币,同比增长均为6.0%。当前股价对应2025年和2026年的市盈率分别为7.4倍和6.9倍,而目标价对应的市盈率为9.4倍和8.8倍,潜在上涨空间为27.1%。二、2025...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10